News & Events

VivaQuant, Inc. Named Finalist for 2021 Tekne Awards

October 26th, 2021

VivaQuant selected as a finalist for the Tekne Medical Technology innovation award for its unique wearable arrhythmia monitor. Read more >

VivaQuant Introduces Smallest One-Piece Mobile Cardiac Telemetry Device

January 28th, 2021

The Rhythm Express RX-1 mini sets a new standard for patient comfort and simplicity. Read more >

VivaQuant Introduces Smallest One-Piece Mobile Cardiac Telemetry Device

January 28th, 2021

The Rhythm Express RX-1 mini sets a new standard for patient comfort and simplicity. Read more >

Minneapolis Star Tribune: VivaQuant is making an intriguing bet on equity crowdfunding

May 19th, 2019

VivaQuant is not anything like the dozen or so Minnesota businesses that have sought funding directly from small investors in the last few years, a list dominated by small craft brewers. VivaQuant doesn’t aspire to be a successful small business. Read more >

VivaQuant Receives FDA 510k Clearance for its RX-1 Rhythm Express Arrhythmia Device

April 30th, 2019

VivaQuant, a digital health company with powerful technology to accurately and efficiently identify and report cardiac arrhythmias, has received FDA clearance for its RX-1 wearable device. Read more >

VivaQuant Inks Collaboration with FDA to Improve Accuracy of Drug Cardiac Safety Assessment

October 2018

Collaboration targets improved understanding of ECG cardiac safety signatures and testing of new methodologies to enhance accuracy of safety assessment. Read more >

VivaQuant Technology Shows Promise for Improving Drug Safety Assessment Accuracy

June 11, 2018

VivaQuant multichannel ECG analysis may improve discrimination of channel block in drug safety studies. Read more >

Society of Toxicology 2018 Meeting

March 12-14, 2018

VivaQuant will have an exhibit booth at the SOT 2018 meeting in San Antonio, Texas from March 12-14. Visit us in booth 1751 to discuss you preclinical or clinical ECG service needs and stop by our poster at location P196 titled Comparison of QT and JTp derived from Spatial Magnitude vs Single-Lead ECG in Beagle Dogs. The poster will be displayed on Monday March 12 with designated author attendance from 1:30-3pm.

LIVE WEBINAR: Improving Preclinical and Clinical Regulatory Submissions Through Enhanced ECG Interval and Arrhythmia Assessment

Thursday, March 1st, 2018 from 11:00 AM – 12:00 PM EST (UTC -5)

Experts in preclinical and clinical ECG safety assessment discuss how advances in arrhythmia detection and concentration effects modelling improve study outcomes. Read more >

VivaQuant Rhythm Express software demonstrates improved accuracy of cardiac safety assessment markers

December 5, 2017

Fully automated QT measurements, obtained from VivaQuant Rhythm Express software, with no human review or editing, were shown to improve accuracy of concentration effect models used in drug safety assessment by 22 percent. Read more >

VivaQuant and DSI Announce Agreement

September 11, 2017

VivaQuant, Inc. and Data Sciences International, Inc. (DSI) announce an agreement for VivaQuant's Rhythm Express ECG Interval and Arrhythmia Analysis Software to support reading of DSI's PonemahTM and DataquestTM data files. This agreement provides new ECG analysis options for Ponemah and Dataquest users. Read more >

VivaQuant Releases AE-1010 Rhythm ExpressTM Software

March 7, 2017

VivaQuant announces the release of AE-1010 Rhythm Express Interval and Arrhythmia Analysis Software for use in research applications. Read more >

VivaQuant Celebrates Eight Years of Success

February 9, 2017

VivaQuant is celebrating eight years since its founding in 2009. Highlights from those eight years include... Read more >

VivaQuant Profiled in CEOCFO Magazine

February 2016

CEOCFO Magazine interviewed VivaQuant CEO Brian Brockway about the company’s technology. Read more (external link) >

VivaQuant Awarded SBIR Grant

January 2016

The National Institutes of Health has awarded a Phase II SBIR grant to VivaQuant for development of a comfortable, accurate, and efficient wearable device for patients with atrial fibrillation. Read more >

Learn how ECG restitution analysis can assess cardiac stress and arrhythmia vulnerability

May 2015

Watch this webinar to learn how ECG restitution analysis, enabled by VivaQuant technology, can help you assess cardiac safety. Access to this link provided courtesy of the Safety Pharmacology Society. Read more (external link) >

VivaQuant CEO and DSITM founder Brian Brockway presents the history of biotelemetry

May 2014

Availability of implantable biotelemetry has played an important role in drug development and biomedical research. This technology has resulted in vastly improved information from research studies and has greatly contributed to reduction and refinement of laboratory animals used in research. Brian Brockway discusses the history of the field and how DSITM came to play a key role in democratizing the use of implantable biotelemetry in research.

DSI is a registered trademark of Data Sciences International.

VivaQuant receives patent award for technique to remove in-band noise from ECGs without distorting morphology

February 2014

Removing in-band noise while preserving ECG morphology enables significantly increased arrhythmia detection accuracy and interval measurement consistency. These anticipated improvements have indeed been achieved through an implementation of this invention whereby in-band noise have been reduced by 26 dB while preserving ECG morphology. Read more (external link) >

VivaQuant profiled by Mathworks for best practices in embedded code development

March 2014

CTO Dr. Marina Brockway has led VivaQuant’s efforts to develop an efficient and robust process for turning complex signal processing algorithms developed on Matlab into embedded code for efficient execution on an ARM Cortex microcomputing platform. Mathworks profiled VivaQuant’s success in this endeavor in their newsletter, culminating with an invited presentation by Dr. Brockway at the Mathworks North American user group.

VivaQuant Accelerates Development and Validation of Embedded Device for Ambulatory ECG Testing [external link]

VivaQuant wins Drug Safety Council Technology Innovation Award

June 2011

VivaQuant was presented with this prestigious award in recognition of the potential of its MDSP ECG processing technology to improve decision making in cardiac safety assessment of new drugs. Read more (external link) >
© 2020 VivaQuant, Inc. | Sitemap